Stocks to Buy in 2026 for Long Term: Nippon Life, Gravita India Among 5 Stocks that Could Give Double Digit Returns

Why It Matters

These picks signal attractive entry points for investors seeking multi‑sector exposure and above‑average returns in a volatile market, potentially reshaping portfolio allocations for the coming year.

Key Takeaways

• Nippon Life target ₹1,040, 21% upside.
• Polycab target ₹9,630, 12% upside.
• Apollo Tyres target ₹600, 36% upside.
• Gravita India target ₹2,010, 30% upside.
• Corona Remedies target ₹1,866, 18% upside.

Pulse Analysis

Brokerage houses have turned upbeat on a cross‑section of Indian stocks, citing a mix of robust earnings growth, improving balance sheets and sector‑specific catalysts. Asset managers like Nippon Life benefit from rising retail inflows and a maturing mutual fund ecosystem, while Polycab rides the surge in infrastructure spending and electrification. Meanwhile, Apollo Tyres leverages higher tyre demand from both passenger and commercial segments, and Gravita India capitalises on expanding chemical demand in pharma and agro‑inputs. Corona Remedies, a niche player in specialty pharmaceuticals, is poised to gain from increased healthcare spending and regulatory support.

Fundamental analysis underpins each recommendation. Nippon Life’s asset‑under‑management growth and fee‑based revenue model support its 21% upside target. Polycab’s strong order book and cost‑efficiency drive a modest 12% upside, reflecting a more conservative valuation. Apollo Tyres’ turnaround strategy, including capacity expansion and brand revamp, justifies a 36% upside, the highest among the group. Gravita India’s diversified chemical portfolio and export potential underpin a 30% upside, while Corona Remedies’ pipeline of high‑margin products fuels an 18% upside projection. These metrics suggest that valuation gaps, rather than speculative hype, are the primary lure for investors.

For long‑term investors, the diversified exposure across asset management, infrastructure, consumer durables and healthcare offers a hedge against sector‑specific volatility. However, risks remain, such as policy shifts, raw‑material price volatility and global economic headwinds that could compress margins. Savvy portfolio construction should balance these upside prospects with prudent risk management, possibly allocating a modest portion to each stock while monitoring earnings guidance and macro trends. As 2026 approaches, the blend of solid fundamentals and attractive price targets positions these equities as compelling candidates for growth‑oriented investors.